Seasoned corporate finance executive and investor who focuses on private equity, M&A and capital markets strategy. Donald O. Dempster combines operating leadership with board and investor-relations experience, advising growth companies on fundraising, strategic exits and governance. Frequently engaged in cross-border transactions and restructurings, offers sector-agnostic deal execution and portfolio oversight capabilities.
Seasoned corporate finance executive and investor who focuses on private equity, M&A and capital markets strategy. Donald O. Dempster combines operating leadership with board and investor-relations experience, advising growth companies on fundraising, strategic exits and governance. Frequently engaged in cross-border transactions and restructurings, offers sector-agnostic deal execution and portfolio oversight capabilities.
Combines an operator’s focus with private-equity discipline, targeting control and structured minority positions in growth-stage and turnaround situations. Prioritizes deep due diligence, governance-driven value creation and clear exit pathways—favoring capital-efficient deals, cross-border arbitrage and complex restructurings. Allocates capital with a medium-to-long horizon, balancing active board-level intervention and strategic investor relations to de-risk execution. Sector-agnostic but biased toward companies where corporate finance expertise, M&A structuring and capital markets access materially accelerate scale or unlock value.
Combines an operator’s focus with private-equity discipline, targeting control and structured minority positions in growth-stage and turnaround situations. Prioritizes deep due diligence, governance-driven value creation and clear exit pathways—favoring capital-efficient deals, cross-border arbitrage and complex restructurings. Allocates capital with a medium-to-long horizon, balancing active board-level intervention and strategic investor relations to de-risk execution. Sector-agnostic but biased toward companies where corporate finance expertise, M&A structuring and capital markets access materially accelerate scale or unlock value.
| Trades 830 | Longs Won 551/830 66% | Profit Factor 4.57 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $580,775.92 |
| Average Win $175,242.8 | Best Trade (Aug 05) $8.61M | Sharpe Ratio -155.1 |
| Average Loss -$75,743.59 | Worst Trade (Jun 30) -$2.39M | Z-Score 4.83 (100%) |
| Commissions $0 | Avg. Trade Length 1y 2m 3w 3d | Expectancy $90,875.08 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 3,891 | 3,502 | 3,113 | 2,724 | 2,335 | 1,946 | 1,556 | 1,167 | 778 | 389 |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
AAPL Apple Inc. | 71,568 | $14.62M | $22.11M | - | $7.49M | 51.26% | -7.354% |
ABBV AbbVie Inc. | 1,953 | $303,351.38 | $490,085.82 | - | $186,734.44 | 61.56% | -2.513% |
ABNB Airbnb, Inc. | 2,543 | $345,443.13 | $385,315.36 | - | $39,872.23 | 11.54% | -0.368% |
ABT Abbott Laboratories | 48,306 | $5.36M | $5.11M | - | -$251,588.79 | -4.7% | +0.085% |
ACN Accenture plc Class A | 9,090 | $1.13M | $1.51M | - | $377,053.2 | 33.33% | +1.611% |
ADBE Adobe Inc. | 9,906 | $2.41M | $2.48M | - | $72,610.89 | 3.02% | +1.013% |
ADCT ADC Therapeutics S.A. | 33,155 | $50,391.08 | $34,812.75 | - | -$15,578.33 | -30.91% | -5.405% |
ADPT Adaptive Biotechnologies Corporation | 2,525 | $216,140 | $56,989.25 | - | -$159,150.75 | -73.63% | -6.658% |
AG First Majestic Silver Corp | 14,200 | $240,832 | $213,426 | - | -$27,406 | -11.38% | -4.207% |
AMAT Applied Materials, Inc. | 2,290 | $378,099.89 | $1.16M | - | $784,464.43 | 207.48% | +1.176% |
AMGN Amgen Inc. | 19,109 | $5.54M | $7.36M | - | $1.82M | 32.83% | -0.64% |
AMT American Tower Corporation | 1,081 | $176,819.18 | $187,402.16 | - | $10,582.98 | 5.99% | -0.631% |
AMZN Amazon.com Inc | 14,240 | $2.69M | $3.87M | - | $1.17M | 43.5% | +15.321% |
AREN Arena Group Holdings Inc. | 13,800 | $12,282 | $16,560 | - | $4,278 | 34.83% | +2.564% |
AUROW Aurora Innovation, Inc. Warrant | 38,262 | $9,546.37 | $7,652.4 | - | -$1,893.97 | -19.84% | +5.263% |
BABA Alibaba Group Holding Limited SP ADR | 8,799 | $844,528.02 | $1.08M | - | $231,149.73 | 27.37% | +5.098% |
BAC-PL Bank of America Corporation | 318 | $380,379 | $410,188.2 | - | $29,809.2 | 7.84% | +0.287% |
BDTX Black Diamond Therapeutics, Inc. | 16,215 | $44,178.04 | $27,403.35 | - | -$16,774.69 | -37.97% | -1.458% |
BDX Becton, Dickinson and Company | 18,689 | $3.4M | $3.1M | - | -$303,586.55 | -8.93% | +0.103% |
BRK-B Berkshire Hathaway Inc. | 1,278 | $478,630.1 | $653,748.12 | - | $175,118.02 | 36.59% | +0.365% |